NEW YORK – Devyser Diagnostics reported this week that its third quarter net sales rose 4 percent to SEK 48.7 million ($4.5 million) from SEK 46.7 million one year earlier. Net sales were up 7 percent with adjustments for exchange rate fluctuations. The Swedish diagnostics developer posted an after-tax loss of SEK 23.2 million, or SEK 1.41 per share, for the quarter ended Sept. 30 compared to a loss of SEK 6 million, or SEK .37 per share, in the same quarter a year ago.
Enzo Biochem this week reported a 16 percent year-over-year revenue decline for its fiscal fourth quarter due to "a shift in ordering patterns" and a 3 percent revenue increase for its fiscal year 2024, which ended July 31. Revenues for the quarter totaled $7.5 million, while revenues for the fiscal year climbed to $31.9 million from $31.1 million in 2023. Net loss for the year totaled $26.1 million, or $.51 per share, compared to net income of $20.3 million, or $.41 per share, in 2023. The 2024 net loss included a $16.3 million loss from discontinued operations. Enzo, based in Farmingdale, New York, ended the quarter with cash and cash equivalents of $52.4 million. The company's board of directors authorized a cash dividend of $.10 per share of common stock, payable on Dec. 2 to stockholders of record as of Nov. 15.
Cancer assay developer Delfi Diagnostics said this week that its Delfi-Tumor Fraction (Delfi-TF) Monitoring cell-free DNA assay has been selected by Incendia Therapeutics to evaluate treatment response and disease progression in patients enrolled in a Phase I clinical trial. The trial is designed to evaluate the safety and tolerability of Incendia's PRTH-101 alone or in combination with pembrolizumab in adults with advanced or metastatic solid tumors.
23andMe said this week that it has regained compliance with Nasdaq's $1.00 minimum bid price requirement to remain listed on the Nasdaq Capital Market. As a result, the company's class A common stock will continue to trade on the market. The company has also regained compliance with the market's requirement to have a majority independent board and various board committees after it appointed three independent directors this week.
Australian molecular diagnostics company Genetic Signatures reported A$4.7 million (US$3.1 million) in revenues for the first quarter of its fiscal year 2025 this week, an almost fourfold increase over the prior-year period. Sales were boosted by the firm's EasyScreen respiratory pathogen detection kit after the Therapeutic Goods Administration (TGA) authorized the updated version in Australia. During the quarter, the company focused on preparing the US commercial launch of its EasyScreen gastrointestinal parasite detection kit, which received US Food and Drug Administration clearance in June. The company did not report any net income or loss. As of Sept. 30, Genetic Signatures held A$41.3 million in cash, including proceeds from a A$30 million capital raise that was completed in July.
Complete Genomics said this week that it has integrated Nvidia's Parabricks software into its next-generation sequencing DNBSeq platforms. The integration will enable DNBSeq customers to perform "accurate, faster, and more affordable" secondary genome analysis, Complete Genomics said. "By combining our high-quality sequencing data with Parabricks' speed and accuracy, we're enabling researchers to uncover variants more efficiently and cost-effectively, ultimately advancing precision medicine and improving patient outcomes," Complete Genomics VP of Product and Marketing Rob Tarbox said in a statement.
Twist Bioscience and Absci said this week that they are collaborating to design a novel therapeutic antibody against an undisclosed drug target "that potentially impacts multiple disease areas." The work will use Absci's generative artificial intelligence design capabilities and Twist's DNA synthesis and antibody candidate testing platforms. The companies said they are seeking a partner for the clinical development and commercialization of the antibody.
Nest Genomics said last week that its Nest Genetics Copilot software has been added to the Athenahealth Marketplace, an app store in which customers using Athenahealth's electronic health record (EHR) system or other tools can shop for software from companies that integrate with the EHR. Nest Genetics Copilot aims to support physicians as they manage genomics-guided care, with tools for risk assessments, tailored education, genetic test ordering, genetic results, and clinical decision support.
Morrisville, North Carolina-based contract research and development organization Synoligo Biotechnologies said this week that it has added a 5,000-square-foot production facility for high-throughput oligonucleotide synthesis. It includes controlled manufacturing space, process automation, and advanced QC labs and allows the company to deliver more than 10,000 oligonucleotides per day.
Canadian biotech firm Telo Genomics said this week that it has amended its deal with the Mayo Clinic, extending the original 2019 agreement to include Mayo’s participation in the company’s Physician Experience Program using Telo’s TeloView SMM prognostic test for smoldering multiple myeloma (SMM), a precursor to active multiple myeloma. Patient samples will also be used to validate TeloView NDMM, a test in development for newly diagnosed multiple myeloma patients. The validation is being carried out in anticipation of the assay being offered as a laboratory-developed test by Telo. TeloView NDMM would enable the identification of patients who will relapse on first-line therapy within a year or confirm that patients are stable in remission on the treatment. Telo has completed the endpoints for the validation of TeloView SMM, and the test is now offered as an LDT.
IndyGeneUS AI and EncrypGen have merged to form IndyGeneUS Bio, a biofintech company that uses genomic research and blockchain technology. Through partnerships with the Aurum Institute, based in South Africa, and its subsidiary Global Health Innovation, IndyGeneUS Bio will have access to clinico-genomic datasets from Africa. Aurum maintains a biorepository in South Africa that recently selected IndyGeneUS as its exclusive whole-genome sequencing and contract drug manufacturing organization. IndyGeneUS Bio Founder and CEO Yusuf Henriques said in a statement this week that the firm plans to "increase participation in genomic data sharing, improve health outcomes, and deliver financial incentives via DNA Token rewards."
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.